EZH2 and mesothelioma: Our observations clearly indicate that BAP1-deficient mesothelioma is sensitive to the combination of EZH2 inhibition and FGFR inhibition, thereby providing a molecularly rationalized approach that should encourage clinical investigation of the combined therapy with EZH2 and FGFR inhibitors in BAP1-deficient cancer.